Wednesday, 18 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

7:01 AM ET 10-Q
Financial Results Village Farms International, Inc. VFF ▶ Call

Village Farms International Q3 2026 Results: Net Income $9.97M, Down 2.4% YoY

Village Farms International reported total assets of $441.4 million as of September 30, 2026, with a cash position of $79.3 million. The company's common shares outstanding increased to 122,319,352 from 115,722,312 at the end of 2025, while total liabilities remained relatively stable at $112.1 million.

Key figure
Net income $9.97M · -2.4% YoY
7:01 AM ET 8-K
Investor Presentation Prokidney Corp. PROK

Prokidney Investor Presentation

ProKidney Corp. has updated its corporate investor presentation for November 2026, which management intends to use for interactions with investors and analysts. The filing also discloses that the company held $141.9 million in cash, cash equivalents, and marketable securities as of September 30, 2026, with a projected cash runway into mid-2027.

7:01 AM ET 8-K
Capital Raise Precision Biosciences Inc DTIL

Precision Biosciences Capital Raise

Precision BioSciences provided an update on its previously announced public offering of 10,235,077 shares of common stock and 5,893,964 pre-funded warrants. The company expects the net proceeds to extend its cash runway into the fourth quarter of 2029, providing sufficient capital to fund its PBGENE-HBV and PBGENE-DMD clinical programs through key inflection points.

7:01 AM ET 8-K
Financial Results Ionis Pharmaceuticals Inc IONS

Ionis Pharmaceuticals Financial Results

Ionis Pharmaceuticals reported Q3 2026 total revenue of $243 million, a 55% increase year-over-year, driven by commercial revenue and R&D partnerships. The company lowered its 2026 product sales guidance for TRYNGOLZA due to a slower-than-expected launch ramp in the sHTG population, while reaffirming total revenue and cash guidance. Ionis ended the quarter with $1.9 billion in cash and short-term investments.

Term
Q3 2026

“TRYNGOLZA, our first launch in a large indication, represents a new treatment paradigm for the underserved sHTG population. While initial sales progress has been more gradual than anticipated, we are encouraged by the underlying launch fundamentals. Importantly, we have identified clear opportunities to improve performance, and we remain confident in TRYNGOLZA's long-term growth potential.”

Brett P. Monia, Ph.D., chief executive officer of Ionis

“In the third quarter, we generated higher quarter-over-quarter commercial revenue and substantial R&D revenue from partnered medicines while continuing to invest in our innovative wholly owned pipeline. Our commercial revenue growth was driven by DAWNZERA, which continues to gain momentum, supporting our confidence in achieving full-year DAWNZERA product sales guidance.”

Elizabeth L. Hougen, chief financial officer of Ionis
7:01 AM ET 8-K
Financial Results Turn Therapeutics Inc. TTRX

Turn Therapeutics Financial Results

Turn Therapeutics reported Q3 2026 financial results and provided clinical updates on its GX-03 program for atopic dermatitis, noting that 59.3% of patients achieved clear skin in a Phase 2a trial. The company also announced the appointment of former CDC Director Robert R. Redfield as Chief Scientific Officer and expects its current cash to fund operations into Q3 2027.

Term
Q3 2026

“The results from our full Stage 1 trial population give us an important look at how patients responded to GX-03 across a wide range of disease severity and extent. We took what we learned from the initial trial and used it to refine our ongoing Phase 2b trial.”

Bradley Burnam, Chief Executive Officer

“The completed Stage 1 trial gives us a clearer picture of GX-03’s potential, particularly for patients with severe itching. We believe severe itch may also help strengthen confidence in an atopic dermatitis diagnosis, since other skin conditions can look similar on visual examination alone. Our Phase 2b trial is designed to find out whether those results can be repeated in a larger group of patients.”

Robert R. Redfield, M.D., Chief Scientific Officer
7:01 AM ET 8-K
Investor Presentation Walker & Dunlop, Inc. WD

Walker & Dunlop Investor Presentation

Walker & Dunlop, Inc. published an updated investor overview presentation on its website and filed it with the SEC. The presentation provides a strategic overview of the company's multifamily and commercial real estate finance operations as of November 2026. The filing includes standard forward-looking statements and non-GAAP financial measure disclosures.

7:00 AM ET 8-K
Business Update NovoCure Ltd NVCR

NovoCure Business Update

NovoCure received a Not Approvable Letter from the FDA regarding its Premarket Approval (PMA) application for Optune Mya for treating brain metastases from non-small cell lung cancer. The FDA cited uncertainty regarding the degree of clinical benefit rather than safety concerns, and the company plans to meet with the regulator to discuss potential paths forward without additional clinical studies.

7:00 AM ET 8-K
Financial Results Via Transportation, Inc. VIA

Via Transportation Financial Results

Via Transportation reported Q3 2026 financial results with revenue growing 31% year-over-year to $143.5 million, driven by 42% growth in the United States. The company reached a significant profitability milestone as Adjusted Net Loss per Share rounded to breakeven ($0.00) and provided Q4 guidance suggesting potential Adjusted EBITDA profitability.

Term
Q3 2026

“Our team’s outstanding execution delivered a milestone quarter for Via. The acceleration of growth provides further validation for our strategy of building a full stack platform that combines AI-powered software and technology-enabled services for cities and transit agencies.”

Daniel Ramot, Via’s Co-founder and Chief Executive Officer

“We are equally pleased that we achieved these results while making another major step towards our profitability target, and at the same time continued to expand our product offering through Via AI Labs.”

Daniel Ramot, Via’s Co-founder and Chief Executive Officer
6:55 AM ET Form 4
Insider Selling Flutter Entertainment plc FLUT

Flutter Entertainment CFO Robert Coldrake Sells $81.6K of Stock

Robert Coldrake, CFO, sold 991 shares of Flutter Entertainment plc at $82.34 a share, worth $81.6K in total on Nov 5, 2026. Shares held after the trade: 23,888 (-4.0%).

Value
$81.6K
Shares
991
Price
$82.34
Role
CFO
Holding change
-4.0%
Trade date
Nov 5, 2026
6:55 AM ET Form 4
Insider Selling Flutter Entertainment plc FLUT

Flutter Entertainment CEO Daniel Mark Taylor Sells $307K of Stock

Daniel Mark Taylor, CEO, sold 3,727 shares of Flutter Entertainment plc at $82.34 a share, worth $307K in total on Nov 5, 2026. Shares held after the trade: 56,642 (-6.2%).

Value
$307K
Shares
3,727
Price
$82.34
Role
CEO
Holding change
-6.2%
Trade date
Nov 5, 2026
6:54 AM ET 8-K
Financial Results Constellation Energy Corp CEG

Constellation Energy Financial Results

Constellation Energy reported Q3 2026 GAAP net income of $5.19 per share and adjusted operating earnings of $5.06 per share, significantly up from $3.04 a year ago. The company raised its full-year 2026 adjusted operating earnings guidance midpoint to $12.50 - $12.80 per share. Key strategic updates included an agreement to acquire the Rhode Island State Energy Center for $715 million and a $5 billion conditional DOE loan commitment for nuclear uprates.

Term
Q3 2026

“This past quarter Constellation announced agreements that are helping meet one of the nation’s greatest challenges – powering a growing economy while protecting existing customers. These agreements add more than 1,000 megawatts of new, emissions-free generation to the grid and help ensure the continued operations of existing clean power for generations to come. The new megawatts, which are the equivalent of a new large-scale nuclear plant, are coming online with no costs being borne by existing customers.”

Joe Dominguez, chairman, president and chief executive officer of Constellation

“Third quarter adjusted operating earnings were $5.06 per share, compared with $3.04 a year ago. This strong performance allowed us to raise the midpoint of our adjusted operating earnings guidance range for the second time this year.”

Shane Smith, executive vice president and chief financial officer of Constellation
6:52 AM ET 8-K
Financial Results KKR & Co. Inc. KKR

KKR & Co Financial Results

KKR & Co. Inc. reported record financial results for the third quarter of 2026, achieving record Fee Related Earnings, Total Operating Earnings, and Adjusted Net Income per share. The firm highlighted its strong monetization activity, expecting to return over $40 billion to clients in 2026, which would exceed its previous annual record by more than 50%.

Term
Q3 2026

“For the second consecutive quarter, KKR is reporting record Fee Related Earnings, Total Operating Earnings and Adjusted Net Income per share, both on a quarterly and trailing twelve-month basis. We continue to monetize investments and return capital to our clients at record levels. In 2026, we expect to return more than $40 billion to our clients, exceeding our previous annual record by more than 50%.”

Joseph Y. Bae and Scott C. Nuttall, Co-Chief Executive Officers
6:52 AM ET 8-K
Financial Results Target Hospitality Corp. TH

Target Hospitality Financial Results

Target Hospitality reported Q3 2026 revenue of $129.1 million, a 30% increase year-over-year, driven by significant growth in its Workforce Hospitality Solutions segment. Despite the revenue growth, the company reported a net loss of $9.2 million for the quarter. Management highlighted securing over $1.7 billion in multi-year contract awards since January 2026, positioning the company for continued growth in critical infrastructure projects.

Term
Q3 2026

“Our third-quarter results reflect a strategic transformation that is delivering meaningful revenue growth and margin expansion. Since January, we have secured multi-year contract awards representing more than $1.7 billion of revenue and over 10,000 beds. With WHS utilized beds now exceeding 6,200 and additional contracted capacity coming online, we are building a foundation for continued growth into 2027 and beyond. Strong execution and growing contributions from these contracts give us significant momentum.”

Brad Archer, President and Chief Executive Officer

“For customers developing data centers, power generation facilities and other critical infrastructure, attracting and retaining skilled workers is essential to project success. Our vertically integrated, scalable Target Hyper/Scale platform and speed-to-market capabilities differentiate us as a preferred sole-source partner. As adoption grows, we see meaningful potential to expand into value-added adjacencies and capture a greater share of our customers’ total development spend. These advantages underpin the deepest commercial pipeline in our history, with advanced discussions underway on multiple large-scale industrial projects. With a diversified contract portfolio and meaningful financial flexibility, we believe Target is uniquely positioned to capitalize on a multi-decade critical infrastructure build-out. We are firmly committed to converting that opportunity into compounding growth and long-term shareholder value.”

Brad Archer, President and Chief Executive Officer
6:50 AM ET 8-K
Financial Results Ferguson Enterprises Inc. FERG

Ferguson Enterprises Financial Results

Ferguson Enterprises reported third quarter sales of $9.0 billion, a 9.5% increase driven by strong non-residential growth and organic performance. The company raised its full-year 2026 net sales growth guidance to approximately 7% following the acquisition of FloWorks and strong year-to-date execution. Management highlighted the completion of eleven acquisitions this year with aggregate annualized revenue of approximately $1.5 billion.

Term
Q3 2026

“Our expert associates delivered strong third quarter results, with non-residential sales up 15% and residential growth of 6%. We continue to invest organically and through acquisitions to expand our value-added solutions and geographic footprint. We have completed eleven acquisitions this year with an aggregate annualized revenue of approximately $1.5 billion, while preserving a strong balance sheet.”

Kevin Murphy, Ferguson CEO

“While our markets remain mixed, our year-to-date performance and the addition of FloWorks enable us to raise our full year guidance. We expect to continue delivering market outperformance by deploying scale locally and leveraging the long-term growth drivers of water infrastructure, large capital projects, climate and comfort and aging and underbuilt housing.”

Kevin Murphy, Ferguson CEO
6:50 AM ET 8-K
Executive Compensation Wafd Inc WAFD

Wafd Executive Compensation

WaFd, Inc. entered into a letter agreement with Chief Experience Officer Cathy E. Cooper providing for a $1,650,000 lump-sum cash continuity payment. The payment is contingent on her continued employment through the closing of the merger with EverBank Financial Corp. In exchange, Ms. Cooper agreed to waive certain 'good reason' resignation triggers related to her role transition following the merger.

Counterparty
Cathy E. Cooper
6:46 AM ET 8-K
Financial Results loanDepot, Inc. LDI

loanDepot Financial Results

loanDepot reported Q3 2026 financial results, highlighting a strategic shift toward higher-margin home equity lending which drove a 54 basis point increase in gain on sale margin to 399 basis points. Despite a challenging mortgage market and a net loss of $29 million, the company improved operating leverage and realized $25 million in annualized cost savings from productivity initiatives.

Term
Q3 2026

“Our third-quarter results demonstrate the progress we have made transforming loanDepot’s operating model over the last year, despite a significantly more challenging mortgage market throughout 2026. While our third-quarter financial results were impacted by market conditions that became increasingly difficult compared to earlier in the year, the broader momentum in our business is clearly evident when viewed against where we were a year ago.”

Anthony Hsieh, Founder and Chief Executive Officer
6:46 AM ET 8-K
Financial Results NRG Energy, Inc. NRG

NRG Energy Financial Results

NRG Energy reported strong Q3 2026 financial results, including GAAP net income of $561 million and Adjusted EBITDA of $2.01 billion. The company also announced a $4 billion agreement to sell select generation assets to support share repurchases and debt reduction, while reaffirming its full-year 2026 guidance.

“Our 17,000 employees delivered strong third quarter results that reflect the depth of NRG, with our eight million customers and a substantial generation business that produce steady earnings and cash flows.”

Robert Gaudette, President & CEO

“Today’s announcement is about returning more to our shareholders and supporting future growth investments. We remain focused on execution and deliberate about how we allocate capital in pursuit of long-term value.”

Robert Gaudette, President & CEO
6:37 AM ET 8-K
Financial Results CNH Industrial N.V. CNH

CNH Industrial Financial Results

CNH Industrial reported Q3 2026 consolidated revenues of $4.4 billion, which were flat year-over-year, and adjusted diluted EPS of $0.16. Results were impacted by a $156 million non-cash tax charge and $109 million in pre-tax IEEPA tariff refunds. The company also announced an agreement with Kobelco regarding its Construction business to sharpen its focus as a pure-play agriculture machinery OEM.

Term
Q3 2026

“The combination of our third quarter results and our agreement with Kobelco regarding our Construction Equipment business reflect clear progress in the execution of our strategy.”

Gerrit Marx, Chief Executive Officer of CNH

“We continue our rigorous execution, prudent production planning, and building a stronger, more competitive CNH for the cycle dynamics ahead. CNH’s agreement with Kobelco follows a deliberate process to strengthen our construction business and sharpen our focus on our agriculture business.”

Gerrit Marx, Chief Executive Officer of CNH
6:37 AM ET 8-K
Financial Results Somnigroup International Inc. SGI

Somnigroup International Financial Results

Somnigroup International reported record third quarter 2026 net sales of $2.4 billion, an 11% increase driven by the acquisition of Leggett & Platt. While GAAP EPS decreased 10.8% to $0.74 due to acquisition costs, Adjusted EPS rose 9.5% to a record $1.04. The company also declared a quarterly cash dividend of $0.17 per share and revised its full-year 2026 guidance.

Term
Q3 2026

“While executing our strategy in a challenging macroeconomic environment, we delivered strong third-quarter GAAP EPS and record adjusted EPS, reflecting the resilience of our business and our global team. During the quarter, we completed the Leggett & Platt acquisition, improving our leverage, enhancing our supply chain and accelerating product development.”

Scott Thompson, Chairman and CEO
6:36 AM ET 8-K
Financial Results Abeona Therapeutics Inc. ABEO

Abeona Therapeutics Financial Results

Abeona Therapeutics reported Q3 2026 financial results, highlighted by $13.5 million in net ZEVASKYN revenue, an 18% sequential increase. The company completed six ZEVASKYN treatments during the quarter and expanded its qualified treatment center network to eight sites. Additionally, Abeona announced the acquisition of a Phase 3-ready asset, APT-1011, for eosinophilic esophagitis and a $30 million PIPE financing.

Term
Q3 2026

“Maximizing the opportunity for ZEVASKYN remains our number one priority. During the third quarter, we continued to build the commercial foundation for ZEVASKYN, with expansion of our QTC network and more centers gaining firsthand treatment experience.”

Vish Seshadri, Ph.D., Chief Executive Officer of Abeona Therapeutics

“The acquisition of APT-1011 represents an important step in building Abeona into a diversified commercial-stage company, adding a uniquely differentiated late-stage orphan-drug asset with substantial commercial potential in a rapidly growing disease with high unmet need.”

Vish Seshadri, Ph.D., Chief Executive Officer of Abeona Therapeutics
6:35 AM ET 6-K
Financial Results Marti Technologies, Inc. MRT

Marti Technologies Q3 2026 Results: Net Loss of $1.02M, Loss Narrows

Marti Technologies reported a significant revenue increase of 128.1% year-over-year for Q3 2026, reaching $24.7 million, driven primarily by platform subscription growth. The company achieved a positive operating gain of $2.7 million for the quarter, compared to a loss in the prior year, though it maintained a net loss of $1.0 million due to financial expenses.

Key figure
Net loss $1.02M
6:35 AM ET 8-K
Business Update Sable Offshore Corp. SOC

Sable Offshore Business Update

Sable Offshore Corp. reported third quarter 2026 operational results, including average daily net sales volumes of 27 thousand barrels of oil per day and a 13% increase in revenue. The company provided updates on Platform Hondo, noting that physical inspections are scheduled for November with full production expected in December 2026. Additionally, Sable diversified its marketing by adding three new Los Angeles-area refinery customers following a downstream purchaser disruption in October.

6:35 AM ET 8-K
Financial Results Vivid Seats Inc. SEAT

Vivid Seats Financial Results

Vivid Seats reported Q3 2026 financial results, returning to year-over-year growth in Marketplace GOV and Adjusted EBITDA. The company also announced an agreement in principle with term lenders for a recapitalization transaction intended to reduce funded debt by approximately $200 million and provide $60 million in new money term loans.

Term
Q3 2026

“We are excited to announce the start of a new era for Vivid Seats. In the third quarter we returned to year-over-year GOV and Adjusted EBITDA growth, reflecting continued successful execution of our strategic priorities. We are equally excited to announce that we have reached an agreement in principle with a substantial majority of our term loan lenders for a recapitalization transaction that will provide us with a durable capital structure to support long-term value creation.”

Lawrence Fey, Chief Executive Officer of Vivid Seats
6:34 AM ET 8-K
Clinical Trial Data ImmunityBio, Inc. IBRX

ImmunityBio Clinical Trial Data

ImmunityBio announced that its QUILT-2.005 trial of ANKTIVA plus BCG met its primary efficacy endpoint in patients with BCG-naïve non-muscle invasive bladder cancer (NMIBC). The combination therapy showed a statistically significant improvement in efficacy compared to BCG alone, and the company plans to submit a supplemental Biologics License Application (sBLA) to the FDA by year-end 2026.

6:32 AM ET 8-K
Financial Results Kodiak Gas Services, Inc. KGS

Kodiak Gas Services Financial Results

Kodiak Gas Services reported record Q3 2026 financial results, including record Adjusted EBITDA of $224.5 million and net income of $71.5 million. Driven by strong performance in its Compression and Power Infrastructure segments, the company increased its full-year 2026 Adjusted EBITDA guidance to a range of $840 million to $860 million.

Term
Q3 2026

“Our third quarter results reflect the continued strength and profitability across our core business segments. Both our Compression Infrastructure and Power Infrastructure segments delivered exceptional financial results.”

Mickey McKee, Kodiak's President and Chief Executive Officer

“In Compression Infrastructure, we delivered our third consecutive quarter of 70% adjusted gross margins, as increased operating efficiencies, driven by our focus on technology and cost discipline, offset inflationary pressures.”

Mickey McKee, Kodiak's President and Chief Executive Officer
6:31 AM ET 8-K
M&A Deal Abeona Therapeutics Inc. ABEO

Abeona Therapeutics Signs $20M M&A Deal with Ellodi Pharmaceuticals, L.P.

Abeona Therapeutics acquired substantially all assets related to APT-1011 (now ABO-801), a Phase 3-ready candidate for eosinophilic esophagitis, from Ellodi Pharmaceuticals. The deal was structured with $20 million in upfront equity consideration (4,494,383 shares) and no upfront cash, with Ellodi eligible for $30 million upon FDA approval and up to $30 million in sales milestones plus royalties.

Value
$20M
Counterparty
Ellodi Pharmaceuticals, L.P.

“The acquisition of ABO-801 is an important step in building Abeona into a diversified commercial-stage company with multiple opportunities for value inflection, adding an asset with substantial revenue potential in a rapidly growing disease.”

Vish Seshadri, Ph.D., Chief Executive Officer of Abeona Therapeutics
6:30 AM ET 8-K
Loan & Debt SBA Communications Corp SBAC

SBA Communications $2B Debt Financing with Wells Fargo Bank, National Association

SBA Communications entered into a $2.0 billion senior unsecured Term Loan Credit Agreement, consisting of $1.165 billion in initial term loans and $835 million in delayed draw commitments. The company used the initial proceeds to repay its Series 2021-1C Secured Tower Revenue Securities. The new facility matures on November 6, 2029, and carries interest based on SOFR plus a margin determined by the company's credit ratings.

Value
$2B
Counterparty
Wells Fargo Bank, National Association
Term
3 years
6:30 AM ET 8-K
Leadership Change National Healthcare Properties, Inc. NHP

National Healthcare Properties Leadership Change

National Healthcare Properties, Inc. increased its board size from six to eight members and appointed Jeffrey S. Olson and Craig S. Smith as independent directors. Mr. Olson is the current CEO of Urban Edge Properties, and Mr. Smith is the CEO of Aimbridge Hospitality. Both directors will serve until the 2027 annual meeting of stockholders.

6:30 AM ET Form 4
Insider Buying Studio City International Holdings Ltd MSC

Studio City International Holdings Director Lawrence Yau Lung Ho Buys $17.6K of Stock

Lawrence Yau Lung Ho, Director, bought 63,552 shares of Studio City International Holdings Ltd at $0.2777 a share, worth $17.6K in total on Nov 6, 2026. Shares held after the trade: 463,464,152 (+0.0%).

Value
$17.6K
Shares
63,552
Price
$0.2777
Role
Director
Holding change
+0.0%
Trade date
Nov 6, 2026
6:29 AM ET 10-Q
Financial Results Sable Offshore Corp. SOC

Sable Offshore Q3 2026 Results: Net Loss of $269M, Loss Widens

Sable Offshore Corp. reported total revenue of $154.4 million for the third quarter of 2026, driven by oil and natural gas liquids sales. The company incurred a net loss of $269.3 million for the quarter, primarily due to a $168.7 million loss on derivatives and significant interest expenses related to its debt restructuring.

Key figure
Net loss $269M

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.